Read, Watch or Listen

President Donald Trump struck landmark agreements with Eli Lilly and Novo Nordisk to cut costs for GLP-1 weight loss drugs. Starting next year, monthly out-of-pocket prices for injections and future pills will range from $50 to $350, officials said. Medicare will cover the drugs for obesity beginning mid-2026, with some patients paying a $50 copay and government pricing of $245 for nonstarting doses. A new TrumpRx platform will offer injectables starting at $350, dropping to $250 within two years, and pills at $145 pending approvals. Lilly cut LillyDirect prices, and Medicaid programs can opt into the $245 rate.

Prepared by Christopher Adams and reviewed by editorial team.